Canlyniadau Chwilio - Scott Gettinger

Mireinio'r Canlyniadau
  1. 1
    PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

    PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? gan Scott Gettinger, Katerina Politi

    Cyhoeddwyd 2016
    Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Oncolytic virus immunotherapy: future prospects for oncology

    Oncolytic virus immunotherapy: future prospects for oncology gan Junaid Raja, Johannes Ludwig, Scott Gettinger, Kurt A. Schalper, Hyun S. Kim

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

    SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer gan Kavita M. Dhodapkar, Scott Gettinger, Rituparna Das, Henry Zebroski, Madhav V. Dhodapkar

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial

    An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial gan Ruth McCorkle, Sangchoon Jeon, Elizabeth Ercolano, Mark Lazenby, Amanda Reid, Marianne Davies, Diane Viveiros, Scott Gettinger

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

    Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy gan Jing W. Hughes, Nalini Vudattu, Mario Sznol, Scott Gettinger, Harriet M. Kluger, Beatrice Lupsa, Kevan C. Herold

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

    Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy gan Veronica Shi, Nemanja Rodić, Scott Gettinger, Jonathan S. Leventhal, Julia P. Neckman, Michael Girardi, Marcus Bosenberg, Jennifer Choi

    Cyhoeddwyd 2016
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

    Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) gan Daniel E. Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott Gettinger, Roy S. Herbst, David L. Rimm, Kurt A. Schalper

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer

    Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer gan Johannes Uhlig, Meaghan Dendy Case, Justin D. Blasberg, Daniel J. Boffa, Anne C. Chiang, Scott Gettinger, Hyun S. Kim

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

    Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling gan Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit Fuhrman, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer

    Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer gan Gregory A. Otterson, Miguel A. Villalona‐Calero, William J. Hicks, Xueliang Pan, John Ellerton, Scott Gettinger, John R. Murren

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

    Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy gan Kathleen C. Suozzi, Maximilian Stahl, Christine J. Ko, Anne C. Chiang, Scott Gettinger, Mark D. Siegel, Christopher G. Bunick

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy gan Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S. Henick, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Treatment of Stage IV Non-small Cell Lung Cancer

    Treatment of Stage IV Non-small Cell Lung Cancer gan Mark A. Socinski, Tracey L. Evans, Scott Gettinger, Thomas A. Hensing, Lecia VanDam Sequist, Belinda Ireland, Thomas E. Stinchcombe

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Immune Checkpoint Inhibitor–Associated Pericarditis

    Immune Checkpoint Inhibitor–Associated Pericarditis gan Mehmet Altan, Maria Toki, Scott Gettinger, Daniel E. Carvajal-Hausdorf, Jon Zugazagoitia, John H. Sinard, Roy S. Herbst, David L. Rimm

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Identification of <i>EGFR</i> mutation, <i>KRAS</i> mutation, and <i>ALK</i> gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma

    Identification of <i>EGFR</i> mutation, <i>KRAS</i> mutation, and <i>ALK</i> gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma gan Guoping Cai, Rebecca A. Wong, David C. Chhieng, Gillian H. Levy, Scott Gettinger, Roy S. Herbst, Jonathan Puchalski, Robert Homer, Pei Hui

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas

    High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas gan Vamsidhar Velcheti, Kurt A. Schalper, Xiaopan Yao, Huan Cheng, Mehmet H. Kocoglu, Kavita M. Dhodapkar, Yanhong Deng, Scott Gettinger, David L. Rimm

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Programmed death ligand-1 expression in non-small cell lung cancer

    Programmed death ligand-1 expression in non-small cell lung cancer gan Vamsidhar Velcheti, Kurt A. Schalper, Daniel Carvajal, Valsamo Anagnostou, Konstantinos N. Syrigos, Mario Sznol, Roy S. Herbst, Scott Gettinger, Lieping Chen, David L. Rimm

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing

    Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing gan Azeet Narayan, Nicholas Carriero, Scott Gettinger, Jeannie Kluytenaar, Kevin R. Kozak, Torunn I. Yock, Nicole E. Muscato, Pedro Ugarelli, Roy H. Decker, Abhijit A. Patel

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer

    A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer gan Kimberly L. Johung, Xiaopan Yao, Fangyong Li, James B. Yu, Scott Gettinger, Sarah B. Goldberg, Roy H. Decker, Judith Hess, Veronica Chiang, Joseph N. Contessa

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors

    Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors gan Y. Y. Janjigian, Egbert F. Smit, Leora Horn, Harry J.M. Groen, D. Ross Camidge, Scott Gettinger, Yali Fu, L. Denis, V.A. Miller, William Pao

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: